Searchable abstracts of presentations at key conferences in endocrinology

ea0011p137 | Clinical case reports | ECE2006

Difficulty to distinguish hyperandrogenia due to a tumoral formation or to polycystic ovary syndrome: a case report

Teissier MP , Combes C , Drutel A , Lopez S

A 24-year-old woman complained about secondary amenorrhoea after stopping oral contraceptive whereas she wanted to be pregnant. Physical examination showed an android obesity with a non-progressive but major hirsutism. Endocrinological investigations eliminated pregnancy but revealed on different samples a high plasma testosterone level (from 2.15 to 2.77 ng/ml), in the tumoral range whereas DHEA-sulfate, delta4-androstendione, sex binding protein and prolactine were normal. S...

ea0011p624 | Neuroendocrinology and behaviour | ECE2006

Interest of a single treatment by somatostatin analogues in a macroadenoma secreting TSH and GH

Lopez S , Combes C , Drutel A , Archambeaud Mouveroux F , Teissier MP

We report a case of a 69-years-old woman who complained about progressive tachycardia, sweat and flush. Her single background was a breast cancer five years ago which was considered in remission. A first blood sample analysis showed an elevated rate of T4 whereas TSH was normal. An IgF1 assay was realised because of an acromegalic appearance and was abnormally high for sex and age. Further biological investigations confirmed central hyperthyroidism and acromegalia. Alpha subun...

ea0026p473 | Thyroid cancer | ECE2011

Clinicopathologic significance of BRAF mutation in papillary thyroid carcinoma

Sastre J , Campos Y , LLamazares O , Orradre J L , Vicente A , Marco A , Aso S , Lopez J

Background: Thyroid carcinoma is the most common endocrine malignancy. BRAF (V600E) mutation is the most frequent detected genetic change in papillary thyroid carcinomas (PTC). There are some discrepancies regarding the overall frequency of the mutation, its prevalence in PTC-variants and its relationship with clinicopathological parameters of poor outcome.Aims: To investigate the relationship of clinicopathological features of PTC with BRAF mutation wit...

ea0029p1825 | Thyroid cancer | ICEECE2012

Prognostic markers in Papillary Thyroid Cancer by immunohistochemistry

Castelblanco E. , Gallel P. , Martinez M. , Barrera L. , Capel I. , Moreno P. , Gimenez G. , Puig-Domingo M. , Bella R. , Porta M. , Halperin I. , Lopez S. , Orellana R. , Cameselle J. , Matias-Guiu X. , Mauricio D. , Robledo M. , Maravall J.

Papillary thyroid cancer (PTC) is the most common endocrine malignancy. Its management has not changed significantly in recent decades, and most patients receive the same treatment. Moreover, there are not alternative treatments for low response or aggressive neoplasias. The availability of reliable prognostic markers that would allow the PTC to be identified based on their aggressiveness at the time of diagnosis would derive in an individualized treatment. In a previous study...